I. Background
Advanced salivary gland carcinoma (SGC) is a rare and heterogeneous malignancy. Traditional chemotherapy offers short-lived efficacy with significant toxicity, and immune checkpoint inhibitors (ICIs) benefit only a small subset of patients, with objective response rates (ORR) of only 4.6%-12%.
Human epidermal growth factor receptor 2 (HER2) is a key actionable target in SGC, but prior anti-HER2 therapies have focused on HER2-high populations; the therapeutic value and efficacy for HER2-low SGC remain unclear. New HER2-targeted antibody-drug conjugates (ADCs) can leverage the bystander effect to act on tumors with low HER2 expression, potentially expanding the treatment boundary of SGC. This study, led by Prof. Dongmei Ji’s team at Fudan University Shanghai Cancer Center, is the first biomarker-stratified, prospective evaluation of the domestically developed HER2-targeted ADC trastuzumab rezetecan (SHR-A1811) in advanced salivary gland carcinoma.
II. Study Design
1. Study type: An open-label, single-center, biomarker-stratified Phase II umbrella trial.
2. Enrolled population: 46 patients with unresectable locally advanced or recurrent/metastatic SGC, aged 18-75 years, with ECOG performance status 0-1.
3. Stratification:
- Cohort 1 (HER2-high, n=24): defined as immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridization (ISH)+.
- Cohort 2 (HER2-low, n=22): defined as IHC 1+ or IHC 2+/ISH-.
Intervention: All patients received SHR-A1811 4.8 mg/kg intravenously, every 3 weeks.
4. Primary endpoint: confirmed ORR by RECIST 1.1. Secondary endpoints included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.
III. Study Results
1. Key Efficacy Results
|
Efficacy Indicators |
HER2 High Expression Cohort (n=24) |
HER2 Low Expression Cohort (n=22) |
|
ORR |
91.7% (4 CR, 18 PR) |
45.5% (10 PR) |
|
DCR |
95.80% |
95.50% |
|
Median DOR PFS, OS |
Not reached |
DOR 11.9 months, PFS 12.7 months, OS 21.3 months |
|
Median Follow-up |
21.9 months |
11.3 months |
In HER2-high SGC, SHR-A1811 set a new ORR benchmark in this field, reaching 91.7% and including 4 complete responses (CRs), suggesting deep tumor remission. In HER2-low SGC—traditionally regarded as a population with “no actionable target”—the 45.5% ORR also far exceeded the historical data of traditional chemotherapy (approximately 35%-39%), with median PFS reaching 12.7 months. These findings may suggest broad antitumor potential of this ADC across HER2 expression levels.
2. Safety Results
- Treatment-related adverse events (TRAEs): incidence 97.8%, with Grade ≥3 TRAEs in 41.3%.
- Most common Grade ≥3 adverse events: neutrophil count decrease (32.6%), white blood cell count decrease (15.2%), anemia (10.9%).
- Interstitial lung disease (ILD): incidence 6.5% (3 patients), all Grade 1, with no Grade ≥2 ILD events.
- Serious TRAEs: incidence 4.3% (1 case each of infectious pneumonia and febrile neutropenia).
- No treatment-related deaths or events leading to treatment discontinuation.
IV. Study Highlights
First prospective validation: This study is the first clinical trial in SGC to prospectively stratify by HER2 expression level (high/low) and demonstrate ADC efficacy in the HER2-low cohort, filling a gap in this field.
Distinctive efficacy data: In the HER2-high cohort, the 91.7% ORR is striking, with both median PFS and OS not yet reached, suggesting durable efficacy once achieved. In the HER2-low cohort, clear signals of disease control and survival prolongation were also observed.
Controllable safety profile: Although hematologic toxicity is common, no new safety signals emerged. Of particular note, the ILD incidence (6.5%, all Grade 1) was substantially lower than that reported for similar agents (e.g., the ILD reporting rate for T-DXd in SGC is 29.4%), possibly related to its unique drug-antibody ratio (DAR=6) and optimized plasma stability.
V. Conclusions
For advanced SGC, a rare and refractory tumor, SHR-A1811 demonstrated breakthrough strong antitumor activity in HER2-high patients; at the same time, it is the first to provide prospective evidence that HER2-low SGC patients can also significantly benefit from anti-HER2 ADC therapy. These findings strongly support the use of a graded (rather than dichotomous) assessment of HER2 expression in clinical practice for SGC, to guide the precise application of ADC drugs. This study lays a solid foundation for the comprehensive development of HER2-targeted ADCs in SGC, opening an entirely new treatment pathway especially for the majority of HER2-low patients.
References
[1] Chen GL, Guo YJ, Liu X, et al. Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression. J Clin Oncol. 2026;00:1-11.